Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

D‐dimer level, in association with humoral responses, negatively correlates with survival of porcine islet grafts in non‐human primates with immunosuppression

D‐dimer level, in association with humoral responses, negatively correlates with survival of... AbbreviationsΔdifference from the level at day 0ρSpearman's coefficient of rank correlationCRPC‐reactive proteinDAPI4',6‐diamidino‐2‐phenylindoleELISAenzyme‐linked immunosorbent assayGalGalα1,3GalISimmunosuppressionleveltwavrgtime‐weighted average levelLODlimit of detectionLSECliver sinusoid endothelial cellmAbmonoclonal antibodyNKnatural killerNHPnon‐human primatePITxporcine islet transplantationPTDpost‐transplant dayTpltransplantIntroductionPorcine islets are proposed as a possible alternative source of islet cells to address the shortage of available donor islets that currently limits widespread application of clinical islet transplantation. The therapeutic potential of porcine islets has been demonstrated in non‐human primate (NHP) models, and several research groups, including us, have reported long‐term survival of porcine islet grafts in NHP recipients with the use of anti‐CD154 monoclonal antibody (mAb), which mediates blockade of the CD40/CD154 costimulatory pathway. Anti‐CD154 mAb, the most successful immunosuppression (IS) regimen in porcine islet transplantation (PITx), is not clinically applicable because of thromboembolic complications. Thus, IS including anti‐CD40 mAb, another mediator of the CD40/CD154 costimulatory pathway, and CD40/CD154 pathway‐sparing IS regimens have been studied as alternatives to the anti‐CD154‐based regimen. Recipients of PITx with these alternative IS regimens have successful engraftment and prolonged graft survival. However, in our previous studies, anti‐CD40 mAb was not as successful as anti‐CD154 mAb at sustaining graft function, although the efficacy and effects of both agents were not precisely compared. Interestingly, both IS regimens suppress http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Xenotransplantation Wiley

D‐dimer level, in association with humoral responses, negatively correlates with survival of porcine islet grafts in non‐human primates with immunosuppression

Download PDF
15 pages

Loading next page...
 
/lp/wiley/d-dimer-level-in-association-with-humoral-responses-negatively-iNf0tL1z0U

References (53)

Publisher
Wiley
Copyright
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
ISSN
0908-665X
eISSN
1399-3089
DOI
10.1111/xen.12299
pmid
28417501
Publisher site
See Article on Publisher Site

Abstract

AbbreviationsΔdifference from the level at day 0ρSpearman's coefficient of rank correlationCRPC‐reactive proteinDAPI4',6‐diamidino‐2‐phenylindoleELISAenzyme‐linked immunosorbent assayGalGalα1,3GalISimmunosuppressionleveltwavrgtime‐weighted average levelLODlimit of detectionLSECliver sinusoid endothelial cellmAbmonoclonal antibodyNKnatural killerNHPnon‐human primatePITxporcine islet transplantationPTDpost‐transplant dayTpltransplantIntroductionPorcine islets are proposed as a possible alternative source of islet cells to address the shortage of available donor islets that currently limits widespread application of clinical islet transplantation. The therapeutic potential of porcine islets has been demonstrated in non‐human primate (NHP) models, and several research groups, including us, have reported long‐term survival of porcine islet grafts in NHP recipients with the use of anti‐CD154 monoclonal antibody (mAb), which mediates blockade of the CD40/CD154 costimulatory pathway. Anti‐CD154 mAb, the most successful immunosuppression (IS) regimen in porcine islet transplantation (PITx), is not clinically applicable because of thromboembolic complications. Thus, IS including anti‐CD40 mAb, another mediator of the CD40/CD154 costimulatory pathway, and CD40/CD154 pathway‐sparing IS regimens have been studied as alternatives to the anti‐CD154‐based regimen. Recipients of PITx with these alternative IS regimens have successful engraftment and prolonged graft survival. However, in our previous studies, anti‐CD40 mAb was not as successful as anti‐CD154 mAb at sustaining graft function, although the efficacy and effects of both agents were not precisely compared. Interestingly, both IS regimens suppress

Journal

Xenotransplantation – Wiley

Published: May 1, 2017

Keywords: ; ; ; ;

There are no references for this article.